148 related articles for article (PubMed ID: 33627375)
1. Epithelial-mesenchymal transition and cancer stem cell interactions in breast phyllodes tumours: immunohistochemical evaluation of EZH2, EZR, HMGA2, CD24 and CD44 in correlation with outcome analysis.
Ahmed SS; Lim JCT; Thike AA; Iqbal J; Tan PH
J Clin Pathol; 2022 May; 75(5):316-323. PubMed ID: 33627375
[TBL] [Abstract][Full Text] [Related]
2. Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression.
Zhang Y; Liss AL; Chung E; Pierce LJ; Kleer CG
Breast Cancer Res Treat; 2016 Jul; 158(1):21-28. PubMed ID: 27290698
[TBL] [Abstract][Full Text] [Related]
3. Expression of cancer stem cell markers in breast phyllodes tumor.
Kim SI; Koo JS
Cancer Biomark; 2020; 29(2):235-243. PubMed ID: 32675396
[TBL] [Abstract][Full Text] [Related]
4. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
[TBL] [Abstract][Full Text] [Related]
5. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
[TBL] [Abstract][Full Text] [Related]
6. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.
Lim JC; Koh VC; Tan JS; Tan WJ; Thike AA; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):19-29. PubMed ID: 25677742
[TBL] [Abstract][Full Text] [Related]
8. Molecules involved in epithelial-mesenchymal transition and epithelial-stromal interaction in phyllodes tumors: implications for histologic grade and prognosis.
Kwon JE; Jung WH; Koo JS
Tumour Biol; 2012 Jun; 33(3):787-98. PubMed ID: 22203494
[TBL] [Abstract][Full Text] [Related]
9. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Vellon L; Menendez JA
Cell Cycle; 2011 Nov; 10(22):3871-85. PubMed ID: 22127234
[TBL] [Abstract][Full Text] [Related]
10. siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
[TBL] [Abstract][Full Text] [Related]
11. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
[TBL] [Abstract][Full Text] [Related]
12. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
Oon ML; Thike AA; Tan SY; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
14. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
16. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
18. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
[TBL] [Abstract][Full Text] [Related]
19. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells.
Han M; Liu M; Wang Y; Mo Z; Bi X; Liu Z; Fan Y; Chen X; Wu C
Mol Cell Biochem; 2012 Apr; 363(1-2):427-36. PubMed ID: 22187223
[TBL] [Abstract][Full Text] [Related]
20. The role of CD44+/CD24-/low biomarker for screening, diagnosis and monitoring of breast cancer.
Camerlingo R; Ferraro GA; De Francesco F; Romano M; Nicoletti G; Di Bonito M; Rinaldo M; D'Andrea F; Pirozzi G
Oncol Rep; 2014 Mar; 31(3):1127-32. PubMed ID: 24366074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]